Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Thursday before the bell. Here’s what ...

Over the last five years, the stock has decreased in 56% of these instances, with a median decline of -3.1% and a maximum ...

The tariffs are Trump’s way of getting drug companies to move more of their operations to the U.S. at a time when domestic ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

Eli Lilly & Company (NYSE:LLY) is one of the top 10 medical AI companies to buy according to analysts. On July 29, the ...

A significant trading signal flashed for Eli Lilly (LLY) at a price of $755.87, after which LLY rose up to 1.8% and closed ...

Eli Lilly is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Learn more on LLY stock here.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

VHT is attractively valued at 16x forward earnings, but sector momentum is weak and technicals remain bearish. Read why VHT ...

He projects LLY’s GLP-1 drug class to deliver revenue of $23 billion and $34 billion in 2025 and 2027, respectively, up from $8 billion in 2022, and then reach $50 billion in 2030.Wall Street ...